摘要:
The present invention provides a polypeptide comprising tetanus toxin fragment C, or a fragment thereof, fused to the pre-S1 region of hepatitis B virus (HBV), or a fragment thereof, and/or the pre-S2 region of HBV or a fragment thereof. It also provides vaccine compositions comprising the polypeptide of the invention.
摘要:
The present invention relates to a compound having anti-KS and anti-HIV pharmaceutical activity which comprises an HCG-like inhibitory protein and fragments or derivatives thereof, said protein and fragments thereof are isolated from a biologically active fraction of APL-HCG, wherein said protein has a molecular weight of about 3,500 or of about 13,000 Dalton, and wherein said protein and fragments thereof are adsorbed polypropylene plastic supports. A pharmaceutical composition for the prevention and/or treatment of Kaposi's sarcoma (KS) and HIV which comprises an therapeutically effective amount of at least one compound of the present invention in association with a pharmaceutically acceptable carrier. A method for the prevention, treatment and/or reduction of Kaposi's sarcoma and HIV expression in AIDS patients, which consists in administering the composition to the patient.
摘要:
The present invention relates to an adjuvant derived from human lymphocytes. The adjuvant can be used in combination with traditional vaccines or cancer immunotherapy, to enhance the response of the patient's immune system to the vaccine or other immunotherapeutic agent. The adjuvant is derived from the supernatant collected from cultured activated lymphocytes.
摘要:
Materials and methods of use thereof are presented for the prophylactic treatment of HIV. Therapeutic compositions including regulated aptamer therapeutic compositions with specificity to components of HIV disease are presented with methods of administering these therapeutic compositions as vaccines against HIV infection.
摘要:
The present invention relates to a method for inducing antibodies neutralizing HIV primary isolates in a mammal, comprising administration of a pharmaceutical composition comprising a polypeptide represented by the formula N-L-C, in which: N represents the amino acid sequence 25-81 of gp41, C represents the amino acid sequence 112-157 of gp41, and L represents a flexible linking sequence comprising from 2 to 30 amino acids.
摘要:
The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same.
摘要:
Methods and compositions for medical imaging, evaluating intracellular processes and components, radiotherapy of intracellular targets, and drug delivery by the use of novel cell membrane-permeant peptide conjugate coordination and covalent complexes having target cell specificity are provided. Kits for conjugating radionuclides and other metals to peptide coordination complexes are also provided.
摘要:
Anti-lentivirus vaccines and immunotherapeutics and methods for preparing and using same are disclosed. The vaccines and immunotherapeutics are produced using non-immunosuppressive lentivirus trans-activator of transcription (Tat) proteins. An associated in vitro ultra-sensitive macrophage Tat bioassay is disclosed for assessing the immunosuppressive qualities of the lentivirus Tat preparations of the present invention. Additionally, a related long-term T4 cell propagation system for characterizing lentivirus Tat is also disclosed. The present invention has additional utility in the treatment and prevention of AIDS.
摘要:
A method and composition for the treatment of pathogenic diseases was developed using the mechanism of RNA interference. The method uses double-stranded RNA to activate the RNA interference pathways within mammalian or pathogen cells. The method can be used to treat any diseases which are caused by or associated with pathogens. A method for identifying double-stranded RNAs useful for the treatment of pathogenic diseases is also presented, as well as model systems which allow this identification. Also described are methods in which siRNAs are used for the inhibition of HIV replication in human cells, as well as the inhibition of RSV pathogenesis in chick embryos.